# Keros Therapeutics

Type: Company (KROS)

Source: GetYourBrief — https://getyourbrief.com/entity/keros-therapeutics
Canonical HTML page: https://getyourbrief.com/entity/keros-therapeutics

## Timeline

- **2026-03-04**: FY 2025 Earnings — Released full-year financial results and updated 2026 clinical guidance.
- **2026-03-04**: FY 2025 Earnings — Official reporting of full-year financial results and 2026 clinical guidance.
- **2026-03-04**: FY2025 Earnings — Released full-year results highlighting commercial scaling and Colorado facility progress.
- **2026**: Anticipated Data — Expected top-line data readouts for multiple Phase 2 programs.
- **2026**: Cibotercept Data — Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
- **2026 (projected)**: Brighton Fab Launch — Expected commencement of high-volume manufacturing in Colorado.
- **2025-Q3**: Cibotercept Progress — Initiated additional cohorts in PAH studies to evaluate dose-response.
- **2025-Q3**: KER-050 Expansion — Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
- **2025-Q3**: 500 Wh/kg Milestone — Verified performance of 500 Wh/kg cells with key aerospace partners.
- **2025-Q1**: Trial Expansion — Keros expanded the TROPOS trial to include broader MDS patient populations.
- **2025-Q1**: Capital Infusion — Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
- **2025-Q1**: Capacity Expansion — Amprius increased production capacity at its Fremont pilot line to meet initial eVTOL demand.

## Recent coverage (3 stories, network-wide)

### Amprius Technologies FY2025: Silicon Anode Scaling and Aviation Decarbonization
2026-03-04 23:38:39 · Sector: climate · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Amprius Technologies reported its full-year 2025 financial results, highlighting a critical transition from pilot-scale production to industrial commercialization of its high-energy silicon anode batteries. The company is positioning its ultra-high-density storage solutions as the primary enabler for the burgeoning eVTOL and defense aviation sectors.
Full story: https://getclimatebrief.com/story/amprius-technologies-fy2025-earnings-analysis

### Keros Therapeutics Strengthens TGF-β Pipeline as 2025 Financials Signal Growth
2026-03-04 23:38:04 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Full story: https://getbiobrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis

### Keros Therapeutics Advances TGF-β Pipeline Amid Q4 2025 Financial Results
2026-03-04 23:37:29 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.
Full story: https://gethealthbrief.com/story/keros-therapeutics-q4-2025-financial-results-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.